# A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

> **NCT06508762** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 24 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-993

## Key facts

- **NCT ID:** NCT06508762
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-26
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-09-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508762, "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06508762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*